Rabini R A, Antosiewicz J, Staffolani R, Polenta M, Testa I, Mazzanti L
Istituto di Biochimica, Università di Ancona.
Boll Soc Ital Biol Sper. 1991 Feb;67(2):129-35.
We studied 10 patients affected by primary hypercholesterolemia treated with placebo for 1 month and with simvastatin (20 mg die) for 6 months during a double-blind clinical trial. At 1-month intervals we determined the following parameters in the serum: total and HDL-cholesterol, triglycerides, apolipoprotein A1 and B. At the same time intervals, we also determined the cholesterol and phospholipid concentration, the Na+/K+ ATPase activity and the fluidity of the erythrocyte membranes. Our results demonstrated the following modifications in the erythrocyte membranes during simvastatin treatment: 1) an initial increase in the cholesterol concentration and in the cholesterol/phospholipid ratio, with a significant decrease only after 4 months; 2) a similar behaviour of membrane fluidity, with an initial decrease and an elevation after 4 months; 3) an increase in the Na+/K+ ATPase activity only after 4 months. We hypothesize that simvastatin not only inhibits the hepatic synthesis of cholesterol, but also modifies the cholesterol exchange between plasma and the erythrocyte membrane.
在一项双盲临床试验中，我们研究了10例原发性高胆固醇血症患者，他们先接受1个月的安慰剂治疗，然后接受辛伐他汀（每日20毫克）治疗6个月。每隔1个月，我们测定血清中的以下参数：总胆固醇和高密度脂蛋白胆固醇、甘油三酯、载脂蛋白A1和B。在相同的时间间隔，我们还测定了胆固醇和磷脂浓度、Na+/K+ ATP酶活性以及红细胞膜的流动性。我们的结果显示，在辛伐他汀治疗期间，红细胞膜有以下变化：1）胆固醇浓度和胆固醇/磷脂比值最初升高，仅在4个月后显著下降；2）膜流动性有类似变化，最初下降，4个月后升高；3）仅在4个月后Na+/K+ ATP酶活性增加。我们推测，辛伐他汀不仅抑制肝脏胆固醇合成，还改变血浆与红细胞膜之间的胆固醇交换。
